MYCN and nut midline carcinoma: Eligibility for this second criterion includes: MYCN amplification or high copy number gain, MYC amplification or high copy number gain, translocation involving MYC or MYCN, translocation involving BRD4 or BRD3, BRD4 amplification or high copy number gain, and/or histologic diagnosis of NUT midline carcinoma (NMC).